Date: 2017-09-04
Type of
information: Publication of results in a medical journal
phase: preclinical
Announcement: publication of results in in Antimicrobial Agents and Chemotherapy
Company: Da Volterra (France)
Product: DAV131
Action
mechanism: DAV131A is an activated charcoal-based adsorbent.
Disease: Clostridium difficile infection
Therapeutic
area: Infectious diseases
Country:
Trial
details:
Latest
news:
- • On September 4, 2017, Da Volterra, a biotechnology company located in Paris, France, is developing breakthrough therapies to combat antibiotic resistance and prevent Clostridium difficile infections (CDI) via protection of the intestinal microbiota during antibiotic treatments. A recent publication by Da Volterra in Antimicrobial Agents and Chemotherapy shows that DAV131, an absorbent based therapeutic, prevents CDI related death in hamsters when given in combination with moxifloxacin. DAV131 is the rodent-adapted form of DAV132 that is designed to prevent C. difficile infections for at risk human patients. This new publication demonstrates that the innovative strategy, on which DAV132 is based, is able in hamsters to prevent CDI infections triggered by treatments with antibiotics such as moxifloxacin.
Is
general: Yes
